Loading…

SARS-CoV-2 nucleic acid testing is China's key pillar of COVID-19 containment

By Jan 31, 2020, the National Medical Products Administration urgently approved six nucleic acid detection kits, and post-market evaluation with a multicentre clinical trial was completed by professional institutions by the end of February, 2020. NAAT laboratories have been in development across Chi...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2022-04, Vol.399 (10336), p.1690-1691
Main Authors: Han, Xiaoxu, Li, Jinming, Chen, Yu, Li, Yan, Xu, Yingchun, Ying, Binwu, Shang, Hong
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:By Jan 31, 2020, the National Medical Products Administration urgently approved six nucleic acid detection kits, and post-market evaluation with a multicentre clinical trial was completed by professional institutions by the end of February, 2020. NAAT laboratories have been in development across China for decades; thousands of NAAT laboratories for detecting infectious agents such as hepatitis B virus, hepatitis C virus, and HIV are established in large hospitals, blood centres, and in the Chinese Center for Disease Control and Prevention. To improve the efficiency of mass screening, China has adopted the sample pooling strategy in three patterns (five, ten, or 20 pooled samples) on the basis of different epidemic periods.4,5 With the optimisation of sample pooling methodology and development of an electronic information system, this sample pooling strategy ensures both high sensitivity and efficiency.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(22)00577-3